Sugi Predict

Sugi Predict / Compounds / SCHEMBL5282712

SCHEMBL5282712

SCHEMBL5282712

CC(C)(C)[Si](OC(CC(=O)O)C(=O)O)(c1ccccc1)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.39
▸ SRR Q9GZT4 3/20 0.37
▸ CPA1 P15085 2/20 0.36
▸ GABBR2 O75899 1/20 0.36
▸ GABBR1 Q9UBS5 1/20 0.36
▸ CPB1 P15086 1/20 0.36
▸ CPA3 P15088 1/20 0.36
▸ CPB2 Q96IY4 1/20 0.36
▸ FFAR1 O14842 4/20 0.35
▸ CYP2C19 P33261 1/20 0.34
▸ HIF1A Q16665 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ PSAT1 Q9Y617 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ GLA P06280 1/20 0.34
▸ CYP3A4 P08684 1/20 0.33
▸ HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1295811 0.86 SMN1; SMN2 (0.42) SRRSMN1; SMN2ALDH1A1
SCHEMBL5970585 0.86 SMN1; SMN2 (0.42) SRRSMN1; SMN2ALDH1A1
SCHEMBL1929736 0.86 SMN1; SMN2 (0.42) SRRSMN1; SMN2ALDH1A1
SCHEMBL31647804 0.85 FOLH1 (0.39) SRRCPA3CYP2C19ALDH1A1GLA
SCHEMBL4753942 0.84 MAPT (0.39) MAPTSRRALDH1A1
SCHEMBL8108093 0.84 MAPT (0.39) MAPTSRRALDH1A1
SCHEMBL5970973 0.84 PPARG (0.47) SRRSMN1; SMN2ALDH1A1CYP3A4
SCHEMBL5747649 0.83 MAPT (0.40) MAPTCPA1GABBR2GABBR1CPB1
SCHEMBL3777347 0.83 MAPT (0.40) MAPTCPA1GABBR2GABBR1CPB1
SCHEMBL5831033 0.83 MAPT (0.40) MAPTCPA1GABBR2GABBR1CPB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007005249-A2 NANOPARTICLES AND DENDRITIC-POLYMER-BASED HYDROGELS COMPRISING THEM HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) 2007-01-11 — — WO disclosed
WO-2007001926-A2 LOW-SWELLING HYDROGEL SEALANTS FOR WOUND REPAIR HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) 2007-01-04 — — WO disclosed
US-7115591-B2 Pyridazinone compounds as cyclooxygenase [COX] 2 inhibitorsfor gastrointestinal disorders ABBOTT LABORATORIES (US) 2006-10-03 — — US disclosed
WO-2006031358-A2 DENDRITIC POLYMERS, CROSSLINKED GELS, AND THEIR USES AS OPHTHALMIC SEALANTS AND LENSES HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) 2006-03-23 — — WO disclosed
WO-2006031388-A2 DENTRITIC POLYMERS, CROSSLINKED GELS, AND THEIR USES IN ORTHOPEDIC APPLICATIONS HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) 2006-03-23 — — WO disclosed
US-20040158064-A1 Prostaglandin endoperoxide H synthase biosynthesis inhibitors BLACK LAWRENCE A (US) 2004-08-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158064-A1 Prostaglandin endoperoxide H synthase biosynthesis inhibitors PTGS1, PTGIS, PTGS2 MAPT 4845/4885SRR 1080/4885CPA1 1496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.